Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_assertion type Assertion NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_head.
- NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_assertion description "[PIK3CA mutations occurred more frequently in KRAS-mutated samples (7/18, 38.9%; p = 0.06) than in KRAS wild type (17/90, 18.9%) and showed a very high frequency in metastatic tumors (4/9, 44.4%; p = 0.1) and in samples displaying serous differentiation-serous and mixed endometrioid/serous tumors (6/12, 50.0%; p = 0.021)-where KRAS mutations were rare (11.1% and 16.7%, respectively) and did not exist independently of a PIK3CA mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_provenance.
- NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_assertion evidence source_evidence_literature NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_provenance.
- NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_assertion SIO_000772 19839777 NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_provenance.
- NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_assertion wasDerivedFrom befree-2016 NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_provenance.
- NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_assertion wasGeneratedBy ECO_0000203 NP770105.RA2mvieZhni7KE62yh7XDvglL31JYErujwn-AtOL6iL2s130_provenance.